1994
DOI: 10.1007/978-1-4757-0414-3
|View full text |Cite
|
Sign up to set email alerts
|

The Handbook of Radiopharmaceuticals

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
20
0
5

Year Published

2004
2004
2019
2019

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 16 publications
(25 citation statements)
references
References 0 publications
0
20
0
5
Order By: Relevance
“…In nuclear medicine, these radiopharmaceuticals are employed in the study of blood flow, metabolism, morphology of an organ and to evaluate the drug formulation and drug delivery systems (Chandra, 1998;Perkins and Frier, 1999). According to Hesselewood and Leung (1994), Owunwanne and Collaborators (1995) and Saha (1998), one of these radiopharmaceuticals is the well known methylenediphosphonic acid labeled with 99m Tc ( 99m Tc-MDP), which is used to perform bone scintigraphy (Owunwanne et al, 1995;Saha, 1998). The 99m Tc-MDP has been used for bone scanning and for the localization of primary bone tumours, metastatic tumours and metabolic bone diseases.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…In nuclear medicine, these radiopharmaceuticals are employed in the study of blood flow, metabolism, morphology of an organ and to evaluate the drug formulation and drug delivery systems (Chandra, 1998;Perkins and Frier, 1999). According to Hesselewood and Leung (1994), Owunwanne and Collaborators (1995) and Saha (1998), one of these radiopharmaceuticals is the well known methylenediphosphonic acid labeled with 99m Tc ( 99m Tc-MDP), which is used to perform bone scintigraphy (Owunwanne et al, 1995;Saha, 1998). The 99m Tc-MDP has been used for bone scanning and for the localization of primary bone tumours, metastatic tumours and metabolic bone diseases.…”
Section: Introductionmentioning
confidence: 99%
“…Many authors have been studying the drug interaction as an important factor that can alter the behavior of the radiopharmaceuticals in different organs and tissues of the animal models (Owunwanne et al, 1998;Mattos et al, 1999;Xavier Holanda et al, 2002;Amorim et al, 2003;Britto et al 2004;. Frequently, this phenomenon is responsible for modification of the bioavailability of the radiopharmaceutical (Owunwanne et al, 1995;Hung et al, 1996;Xavier Holanda et al, 2002;Gomes et al, 2002). Thus, the nuclear medicine practices have increased continually in recent decades.…”
Section: Introductionmentioning
confidence: 99%
“…Figures 1 and 2 show respectively the distribution of free molybdenum and molybdenum combined to MDP in planar chromatography using 0.9% NaCl solution and Propanone as mobile phases. It is known that MDP presents high affinity to NaCl 0.9% solution as well as to technetium in the form of pertechnetate (Owunwanne, 1995). Such characteristic is not observed in molybdenum, which presents higher affinity to the medium.…”
Section: Discussionmentioning
confidence: 97%
“…(Owunwanne, 1995). Molybdenum decays by beta emission to 99m Tc (87%) and 99 Tc (13%), emitting photons of 740 and 778 keV and has a half-life of 66 h (LBNL, 2005 Tc-MDP for radionuclide imaging include its rapid clearance from plasma and its high urinary excretion, which contribute to the high contrast between bone and soft tissue.…”
Section: Introductionmentioning
confidence: 99%
“…(Hesslewood and Leung, 1994;Owunwanne et al, 1995;Sampson, 1999). Blood constituents labeled with 99mTc have been used in several clinical examinations (Saha, 2004) and also as an experimental assay on an attempt to verify the effect of drugs ).…”
Section: Discussionmentioning
confidence: 99%